Abstract:Abstract Background Smoking prevalence is higher amongst individuals with schizophrenia and depression compared to the general population. Mendelian randomisation (MR) can examine whether this association is causal using genetic variants identified in genome-wide association studies (GWAS). Methods We conducted a GWAS of lifetime smoking behaviour (capturing smoking duration, heaviness and cessation) in a sample of 462,690 individuals from the UK Biobank, and validated the findings via two-sample MR analyses of positive control outcomes (e.g., lung cancer). Having established the validity of our instrument, we used bi-directional two-sample Mendelian randomisation to explore its effects on schizophrenia and depression. Outcomes There was strong evidence to suggest smoking is a causal risk factor for both schizophrenia (OR = 2.27, 95% CI = 1.67 - 3.08, P < 0.001) and depression (OR = 1.99, 95% CI = 1.71 - 2.32, P < 0.001). We also found some evidence that genetic risk for both schizophrenia and depression cause increased lifetime smoking (β = 0.022, 95% CI = 0.005 - 0.038, P = 0.009; β= 0.091, 95% CI = 0.027 - 0.155, P = 0.005). Interpretation These findings suggest that the association between smoking, schizophrenia and depression is due, at least in part, to a causal effect of smoking, providing further evidence for the detrimental consequences of smoking for mental health. Funding This work was supported by the Medical Research Council Integrative Epidemiology Unit, the NIHR Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Research in context Evidence before this study The association between smoking and mental health (especially schizophrenia and depression) is often assumed to be the result of self-medication (for example, to alleviate symptoms). However, more recent evidence has suggested that smoking might also be a risk factor for schizophrenia and depression. This alternative direction of effect is supported by meta-analyses and previous prospective observational evidence using related individuals to control for genetic and environmental confounding. However, observational evidence cannot completely account for confounding or the possibility of reverse causation. One way to get around these problems is Mendelian randomisation (MR). Previous MR studies of smoking and mental health have not shown an effect of smoking on depression and are inconclusive for the effects of smoking on schizophrenia. However, these studies have only looked at individual aspects of smoking behaviour and some studies required stratifying participants into smokers and non-smokers, reducing power. Added value of this study We have developed a novel genetic instrument for lifetime smoking exposure which can be used within a two-sample MR framework, using publicly-available GWAS summary statistics. We were therefore able to test the bi-directional association between smoking with schizophrenia and depression to see if the effects are causal. We found strong evidence to suggest that smoking is a causal risk factor for both schizophrenia and depression. There was some evidence to suggest that risk of schizophrenia and depression increases lifetime smoking (consistent with the self-medication hypothesis) but the effects were stronger for depression than schizophrenia. Implications of all the available evidence This study was the first to demonstrate evidence for an effect of lifetime smoking exposure on risk of schizophrenia and depression within a causal inference framework. This emphasises the detrimental public health consequences of smoking, not just for physical health, but also to mental illness.

Examining the independent roles of cannabis use and tobacco use in depression risk: a multivariable Mendelian randomisation study

Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomization study

Associations of cannabis use, tobacco use, and incident anxiety, mood, and psychotic disorders: a systematic review and meta-analysis

Association of Cannabis Use Disorder with Cardiovascular Diseases: A Two-Sample Mendelian Randomization Study

Determination of shared genetic etiology and possible causal relations between tobacco smoking and depression

Cannabis use, depression and self-harm: phenotypic and genetic relationships

The impact of cannabis use on erectile dysfunction and sex hormones: a Mendelian randomization analysis

Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking

Causal effects of lifetime smoking on risk for depression and schizophrenia: Evidence from a Mendelian randomisation study

Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking

Understanding the role of cannabis use on cigarette dependence severity among individuals with e-cigarette and combustible tobacco dual use

Cigarette Smoking and Schizophrenia: Mendelian Randomisation Study.

Depression screening outcomes among adolescents, young adults, and adults reporting past 30-day tobacco and cannabis use

Genetic Support of a Causal Relationship Between Cannabis Use and Educational Attainment: a Two-Sample Mendelian Randomization Study of European Ancestry.

Investigating the causal effects of smoking, sleep, and BMI on major depressive disorder and bipolar disorder: a univariable and multivariable two-sample Mendelian randomization study

Trends of major depressive episode among people with cannabis use: Findings from the National Survey on Drug Use and Health 2006–2015

Association between cannabis use and brain structure and function: an observational and Mendelian randomisation study

Association between tobacco smoke exposure and depression: the NHANES 2005-2018 and Mendelian randomization study

GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability

Prevalence of depressive symptoms and cannabis use among adult cigarette smokers in Canada: cross-sectional findings from the 2020 International Tobacco Control Policy Evaluation Project Canada Smoking and Vaping Survey